These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 22349253)

  • 21. Vaginal DHEA to treat menopause related atrophy: a review of the evidence.
    Panjari M; Davis SR
    Maturitas; 2011 Sep; 70(1):22-5. PubMed ID: 21733647
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effect of raloxifene on sexual function in postmenopausal women.
    Kessel B; Nachtigall L; Plouffe L; Siddhanti S; Rosen A; Parsons A
    Climacteric; 2003 Sep; 6(3):248-56. PubMed ID: 14567773
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effectiveness and safety of vaginal suppositories for the treatment of the vaginal atrophy in postmenopausal women: an open, non-controlled clinical trial.
    Costantino D; Guaraldi C
    Eur Rev Med Pharmacol Sci; 2008; 12(6):411-6. PubMed ID: 19146203
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Interrelationships of serum estradiol, estrone, and estrone sulfate, adiposity, biochemical bone markers, and leptin in post-menopausal women.
    Castracane VD; Kraemer GR; Ogden BW; Kraemer RR
    Maturitas; 2006 Jan; 53(2):217-25. PubMed ID: 15913927
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Concentration range of serum sex steroids in normal postmenopausal women and those with diagnosis of vulvovaginal atrophy.
    Ke Y; Bélanger A; Simard JN; Gonthier R; Martel C; Vaillancourt M; Labrie F
    Menopause; 2018 Mar; 25(3):293-300. PubMed ID: 29206779
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Conjugated estrogens (Premarin) vaginal cream.
    Med Lett Drugs Ther; 2009 Feb; 51(1306):14-5. PubMed ID: 19229162
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Estradiol, estrone, and gonadotropin levels after use of vaginal estradiol.
    Martin PL; Greaney MO; Burnier AM; Brooks PM; Yen SS; Quigley ME
    Obstet Gynecol; 1984 Apr; 63(4):441-4. PubMed ID: 6422370
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Use of Growth Factors for Vulvo/Vaginal Bio-Stimulation.
    Isaza PG
    Surg Technol Int; 2019 May; 34():269-273. PubMed ID: 30388724
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Efficacy and safety of vaginal estriol and progesterone in postmenopausal women with atrophic vaginitis.
    Chollet JA; Carter G; Meyn LA; Mermelstein F; Balk JL
    Menopause; 2009; 16(5):978-83. PubMed ID: 19390463
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Plasma estrogen concentrations after oral and vaginal estrogen administration in women with atrophic vaginitis.
    Dorr MB; Nelson AL; Mayer PR; Ranganath RP; Norris PM; Helzner EC; Preston RA
    Fertil Steril; 2010 Nov; 94(6):2365-8. PubMed ID: 20466363
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effects of vaginally delivered estrogens.
    Heimer G; Samsioe G
    Acta Obstet Gynecol Scand Suppl; 1996; 163():1-2. PubMed ID: 8916468
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effect of estradiol valerate and levonorgestrel on vaginal health.
    Manonai J; Chittacharoen A; Theppisai U
    Eur J Obstet Gynecol Reprod Biol; 2004 Aug; 115(2):190-3. PubMed ID: 15262354
    [TBL] [Abstract][Full Text] [Related]  

  • 33. LC-MS/MS coupled with immunoaffinity extraction for determination of estrone, 17beta-estradiol and estrone 3-sulfate in human plasma.
    Hosogi J; Tanaka H; Fujita K; Kuwabara T; Ikegawa S; Kobayashi N; Mano N; Goto J
    J Chromatogr B Analyt Technol Biomed Life Sci; 2010 Jan; 878(2):222-7. PubMed ID: 19700374
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Vaginal estrogen preparations: a review of safety and efficacy for vaginal atrophy.
    Crandall C
    J Womens Health (Larchmt); 2002 Dec; 11(10):857-77. PubMed ID: 12626086
    [TBL] [Abstract][Full Text] [Related]  

  • 35. An overview of chronic vaginal atrophy and options for symptom management.
    Woods NF
    Nurs Womens Health; 2012 Dec; 16(6):482-93; quiz 494. PubMed ID: 23253575
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Estrone/17beta-estradiol conversion to, and tumor necrosis factor inhibition by, estrogen metabolites in synovial cells of patients with rheumatoid arthritis and patients with osteoarthritis.
    Schmidt M; Hartung R; Capellino S; Cutolo M; Pfeifer-Leeg A; Straub RH
    Arthritis Rheum; 2009 Oct; 60(10):2913-22. PubMed ID: 19790073
    [TBL] [Abstract][Full Text] [Related]  

  • 37. EMAS clinical guide: low-dose vaginal estrogens for postmenopausal vaginal atrophy.
    Rees M; Pérez-López FR; Ceasu I; Depypere H; Erel T; Lambrinoudaki I; Schenck-Gustafsson K; Simoncini T; van der Schouw Y; Tremollieres F;
    Maturitas; 2012 Oct; 73(2):171-4. PubMed ID: 22818886
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Systemic estradiol levels with low-dose vaginal estrogens.
    Santen RJ; Mirkin S; Bernick B; Constantine GD
    Menopause; 2020 Mar; 27(3):361-370. PubMed ID: 31794498
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Plasma estrone sulfate assay in men: Comparison of radioimmunoassay, mass spectrometry coupled to gas chromatography (GC-MS), and liquid chromatography-tandem mass spectrometry (LC-MS/MS).
    Giton F; Caron P; Bérubé R; Bélanger A; Barbier O; Fiet J
    Clin Chim Acta; 2010 Sep; 411(17-18):1208-13. PubMed ID: 20427015
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Estrogen and its effect on vaginal atrophy in post-menopausal women.
    Kelley C
    Urol Nurs; 2007 Feb; 27(1):40-5. PubMed ID: 17390926
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.